Drug Trial Radar · NCT04195399
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
31
Actual
Start
Oct 7, 2020
Primary completion
Mar 31, 2026
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- First posted
- Dec 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions
- Desmoid Fibromatosis
- Recurrent Desmoid Fibromatosis
- Unresectable Desmoid Fibromatosis
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT
Echocardiography TestProcedure
Undergo ECHO
Magnetic Resonance ImagingProcedure
Undergo MRI
Nirogacestat HydrobromideDrug
Given PO
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
X-Ray ImagingProcedure
Undergo x-ray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Up to 2 years from study entry
- Percentage of patients experiencing grade 3+ adverse events (AE)Time frame: Up to 6 years from study entry
- Pharmacokinetic (PK) parameter: systemic exposureTime frame: Up to Cycle 3 (each cycle lasts 28 days)
- PK parameter: drug clearanceTime frame: Up to Cycle 3 (each cycle lasts 28 days)
- PK parameter: half-lifeTime frame: Up to Cycle 3 (each cycle lasts 28 days)
Locations
98 sites in 5 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
USA Health Strada Patient Care Center
Mobile, Alabama
Banner Children's at Desert
Mesa, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Kaiser Permanente Downey Medical Center
Downey, California
Loma Linda University Medical Center
Loma Linda, California
Children's Hospital Los Angeles
Los Angeles, California
Mattel Children's Hospital UCLA
Los Angeles, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Lucile Packard Children's Hospital Stanford University
Palo Alto, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Rady Children's Hospital - San Diego
San Diego, California
UCSF Medical Center-Mission Bay
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Alfred I duPont Hospital for Children
Wilmington, Delaware
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Children's National Medical Center
Washington D.C., District of Columbia
UF Health Cancer Institute - Gainesville
Gainesville, Florida
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida
AdventHealth Orlando
Orlando, Florida
Nemours Children's Hospital
Orlando, Florida
Johns Hopkins All Children's Hospital
St. Petersburg, Florida
Saint Joseph's Hospital/Children's Hospital-Tampa
Tampa, Florida
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii
Saint Luke's Cancer Institute - Boise
Boise, Idaho
Lurie Children's Hospital-Chicago
Chicago, Illinois
University of Chicago Comprehensive Cancer Center
Chicago, Illinois
OSF Children's Hospital of Illinois
Peoria, Illinois
Riley Hospital for Children
Indianapolis, Indiana
Norton Children's Hospital
Louisville, Kentucky
Children's Hospital New Orleans
New Orleans, Louisiana
Ochsner Medical Center Jefferson
New Orleans, Louisiana
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland
Walter Reed National Military Medical Center
Bethesda, Maryland
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.